On May 7, 2019, Chembio Diagnostics announced an agreement with Perseus Science Group, to advance the development of a diagnostic test for mild traumatic brain injury (TBI), or concussion. This agreement built on previous agreements between the two firms that resulted in the completion of technical feasibility to detect Perseusﾒ patented biomarker.